Camila Melo

Dr. Camila Melo

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2020 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
TVThiago Vidotto
Thiago Vidotto
CMCamila Melo
Camila Melo
ECErick Castelli
Erick Castelli
MKMadhuri Koti
Madhuri Koti
RRRodolfo Borges dos Reis
Rodolfo Borges dos Reis
JSJeremy Andrew Squire
Jeremy Andrew Squire
Mutations inPTENactivate the phosphoinositide 3-kinase (PI3K) signalling network, leading to many of the characteristic phenotypic changes of cancer. However, the primary effects of this gene on oncogenesis through control of the PI3K–AKT–mammalian target of rapamycin (mTOR) pathway might not be the only avenue by which PTEN affects tumour progression. PTEN has been shown to regulate the antiviral interferon network and thus alter how cancer cells communicate with and are targeted by immune cells. An active, T cell-infiltrated microenvironment is critical for immunotherapy success, which is also influenced by mutations in DNA damage repair pathways and the overall mutational burden of the tumour. As PTEN has a role in the maintenance of genomic integrity, it is likely that a loss of PTEN affects the immune response at two different levels and might therefore be instrumental in mediating failed responses to immunotherapy. In this review, we summarise findings that demonstrate how the loss of PTEN function elicits specific changes in the immune response in several types of cancer. We also discuss ongoing clinical trials that illustrate the potential utility of PTEN as a predictive biomarker for immune checkpoint blockade therapies.

12 January 2014 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
CMCamila Maria Longo Machado
Camila Maria Longo Machado
LALuciana Andrade
Luciana Andrade
VTVerônica Rodrigues Teixeira
Verônica Rodrigues Teixeira
FCFabrício Falconi Costa
Fabrício Falconi Costa
CMCamila Melo
Camila Melo
Roger ChammasRoger Chammas
Roger Chammas
In order to study the role of galectin‐3 in tumor angiogenesis associated with tumor‐associated macrophages (TAM) and tumor parenchyma, the galectin‐3 expression was reconstituted in Tm1 melanoma cell line that lacks this protein. Galectin‐3‐expressing cells (Tm1G3) and mock‐vector transfected cells (Tm1N3) were injected into wild‐type (WT) and galectin‐3 knockout (KO) C57Bl/6 mice. Tumors originated from Tm1G3 were larger in tumor volume with enlarged functional vessels, decreased necrotic areas, and increased vascular endothelial growth factor (VEGF) protein levels. Galectin‐3‐nonexpressing‐cells injected into WT and KO showed increased levels of transforming growth factor beta 1 (TGFβ1) and, in WT animals this feature was also accompanied by increased VEGFR2 expression and its phosphorylation. In KO animals, tumors derived from galectin‐3‐expressing cells were infiltrated by CD68+‐cells, whereas in tumors derived from galectin‐3‐nonexpressing‐cells, CD68+ cells failed to infiltrate tumors and accumulated in the periphery of the tumor mass. In vitro studies showed that Tm1G3 secreted more VEGF than Tm1N3 cells. In the latter case, TGFβ1 induced VEGF production. Basal secretion of VEGF was higher in WT‐bone marrow‐derived macrophages (BMDM) than in KO‐BMDM. TGFβ1 induced secretion of VEGF only in WT‐BMDM. Tm1G3‐induced tumors had the Arginase I mRNA increased, which upregulated alternative macrophage (M2)/TAM induction. M2 stimuli, such as interleukin‐4 (IL4) and TGFβ1, increased Arginase I protein levels and galectin‐3 expression in WT‐ BMDM, but not in cells from KO mice. Hence, we report that galectin‐3 disruption in tumor stroma and parenchyma decreases angiogenesis through interfering with the responses of macrophages to the interdependent VEGF and TGFβ1 signaling pathways.

27 November 2021 in Genes
Verified
Journal Article
Open access
PDF file
Luiz Paulo Chaves SouzaLuiz Paulo Chaves Souza
Luiz Paulo Chaves Souza
CMCamila Melo
Camila Melo
FSFabiano Pinto Saggioro
Fabiano Pinto Saggioro
RPRodolfo Reis PI
Rodolfo Reis PI
JSJeremy Andrew Squire
Jeremy Andrew Squire
Prostate cancers may reactivate a latent embryonic program called the epithelial–mesenchymal transition (EMT) during the development of metastatic disease. Through EMT, tumors can develop a mesenchymal phenotype similar to cancer stem cell traits that contributes to metastasis and variation in therapeutic responses. Some of the recurrent somatic mutations of prostate cancer affect EMT driver genes and effector transcription factors that induce the chromatin- and androgen-dependent epigenetic alterations that characterize castrate-resistant prostate cancer (CRPC). EMT regulators in prostate cancer comprise transcription factors (SNAI1/2, ZEB1, TWIST1, and ETS), tumor suppressor genes (RB1, PTEN, and TP53), and post-transcriptional regulators (miRNAs) that under the selective pressures of antiandrogen therapy can develop an androgen-independent metastatic phenotype. In prostate cancer mouse models of EMT, Slug expression, as well as WNT/β-Catenin and notch signaling pathways, have been shown to increase stemness potential. Recent single-cell transcriptomic studies also suggest that the stemness phenotype of advanced prostate cancer may be related to EMT. Other evidence correlates EMT and stemness with immune evasion, for example, activation of the polycomb repressor complex I, promoting EMT and stemness and cytokine secretion through RB1, TP53, and PRC1. These findings are helping clinical trials in CRPC that seek to understand how drugs and biomarkers related to the acquisition of EMT can improve drug response.

Verified
Journal Article
Open access
PDF file
CMCamila Melo
Camila Melo
TVThiago Vidotto
Thiago Vidotto
Luiz Paulo Chaves SouzaLuiz Paulo Chaves Souza
Luiz Paulo Chaves Souza
WLWilliam Lautert-Dutra
William Lautert-Dutra
RPRodolfo Reis PI
Rodolfo Reis PI
JSJeremy Andrew Squire
Jeremy Andrew Squire
Immunotherapy has improved patient survival in many types of cancer, but for prostate cancer, initial results with immunotherapy have been disappointing. Prostate cancer is considered an immunologically excluded or cold tumor, unable to generate an effective T-cell response against cancer cells. However, a small but significant percentage of patients do respond to immunotherapy, suggesting that some specific molecular subtypes of this tumor may have a better response to checkpoint inhibitors. Recent findings suggest that, in addition to their function as cancer genes, somatic mutations of PTEN, TP53, RB1, CDK12, and DNA repair, or specific activation of regulatory pathways, such as ETS or MYC, may also facilitate immune evasion of the host response against cancer. This review presents an update of recent discoveries about the role that the common somatic mutations can play in changing the tumor microenvironment and immune response against prostate cancer. We describe how detailed molecular genetic analyses of the tumor microenvironment of prostate cancer using mouse models and human tumors are providing new insights into the cell types and pathways mediating immune responses. These analyses are helping researchers to design drug combinations that are more likely to target the molecular and immunological pathways that underlie treatment failure.

1 December 2017 in Carbohydrate Polymers
Verified
Journal Article
Closed access
SBS.M.P. Biscaia
S.M.P. Biscaia
ECE.R. Carbonero
E.R. Carbonero
DBD.L. Bellan
D.L. Bellan
BBB.S. Borges
B.S. Borges
CCC.R. Costa
C.R. Costa
ETEdvaldo Trindade
Edvaldo Trindade

13 April 2011 in BMC Medical Genomics
Verified
Journal Article
Open access
PDF file
ACAnna EL Coló
Anna EL Coló
ASAna Cq Simoes
Ana Cq Simoes
ACAndré L Carvalho
André L Carvalho
CMCamila Melo
Camila Melo
LFLucas Fahham
Lucas Fahham
ACAlex F Carvalho
Alex F Carvalho
Cancer shows a great diversity in its clinical behavior which cannot be easily predicted using the currently available clinical or pathological markers. The identification of pathways associated with lymph node metastasis (N+) and recurrent head and neck squamous cell carcinoma (HNSCC) may increase our understanding of the complex biology of this disease.